BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor

Chong Li; Ruping Yan; Zhao Yang; Haifeng Wang; Ruiyun Zhang; Haige Chen; Jiansong Wang

doi:10.18632/oncotarget.13504

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor

Chong Li, Ruping Yan, Zhao Yang, Haifeng Wang, Ruiyun Zhang, Haige Chen and Jiansong Wang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:46704-46705. https://doi.org/10.18632/oncotarget.13504

Metrics: PDF 1707 views | HTML 2561 views | ?

Abstract

Chong Li1,5,*, Ruping Yan2,*, Zhao Yang3,*, Haifeng Wang2, Ruiyun Zhang4, Haige Chen4, Jiansong Wang2

1Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

2Department of Urology, The Second Affliated Hospital of Kunming Medical University, Kunming 650101, China

3CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China

4Department of Urology, Renji Hospital Affiliated to Shanghai Jiaotong University, School of Medicine, Shanghai 200127, China

5Beijing Jianlan Institute of Medicine, Beijing 100190, China

*These authors contributed equally to this work

Correspondence to:

Chong Li, email: [email protected]

Jiansong Wang, email: [email protected]

Haige Chen, email: [email protected]

Keywords: BCMab1, BCMab1-Ra, bladder cancer, aberrantly glycosylated integrin a3b1

Received: October 06, 2016 Accepted: November 08, 2016 Published: November 22, 2016

ABSTRACT

Bladder cancer is one of the most common malignancies. However, there is no ideal therapy to cure bladder cancer so far, especially invasive carcinoma. Here, we developed a new antibody-based drug BCMab1-Ra, which was generated by conjugation of BCMab1 (a new monoclonal antibody that specifically recognized the aberrantly glycosylated Integrin a3b1 in bladder cancer) with the ricin A chain (Ra). A patient with multiple bladder cancer received intravescical administration of BCMab1-Ra treatment as a volunteer. After 30 weeks of treatment, no tumor was observed by cystoscope examination. We did not observe any local or systemic side effects. Human anti-mouse antibody (HAMA) was not detectable in the circulation. Results follow-up showed no tumor had been found in every half year review in 3 years.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13504

Publication Alerts

Case Reports:

BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor

Abstract